Next-generation monoclonals less profitable than trailblazers?
- 27 July 2005
- journal article
- Published by Springer Nature in Nature Biotechnology
- Vol. 23 (8) , 906
- https://doi.org/10.1038/nbt0805-906
Abstract
No abstract availableKeywords
This publication has 2 references indexed in Scilit:
- Teva to acquire Chinese biogenerics manufacturerNature Biotechnology, 2005
- Maturing biotechs turn to pharma's marketsNature Biotechnology, 2005